Loading
Latest filing published 25 Jan 2023 for Calithera Biosciences, Inc., €130. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
Stephanie Wong (chief executive) discloses dealings in Calithera Biosciences, Inc. to SEC (Form 4). We count 5 filings; the first trade dates from 27 October 2021 and the latest from 23 January 2023.
Not one of the filings records a straightforward purchase or sale on the market. Because grants and exercises are largely decided by remuneration plans, they are not counted as purchases here.
The newest entry dates from 25 January 2023: a share grant of €130, in Calithera Biosciences, Inc. Typically, a trade is published a median of 2 days after it takes place. US insiders must file a Form 4 within two business days of a trade. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
5 of 5 declarations